59-39-2 | Piperidine,1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	2 weeks	$1,171.00	$820.00
100mg	95%	2 weeks	$2,957.00	$2,070.00

Description

• Catalog Number: AB51999
• Chemical Name: Piperidine,1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-
• CAS Number: 59-39-2
• Molecular Formula: C14H19NO2
• Molecular Weight: 233.3062
• MDL Number: MFCD00242712
• SMILES: C1CCN(CC1)CC1COc2c(O1)cccc2

Computed Properties

• Complexity: 240
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 17
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 2
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.6

Literature

• Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.

  Neuropharmacology 20110101

• Role of alpha-2 adrenergic receptors in anti-ulcer effect mechanism of estrogen and luteinising hormone on rats.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20090401

• Nasal trigeminal inputs release the A5 inhibition received by the respiratory rhythm generator of the mouse neonate.

  Journal of neurophysiology 20040201

• Development of a segmented model for a continuous electrophoretic moving bed enantiomer separation.

  Biotechnology progress 20030101

• Continuous fractionation of enantiomer pairs in free solution using an electrophoretic analog of simulated moving bed chromatography.

  Journal of chromatography. A 20020412

• Use of dyes to investigate migration of the chiral selector in CFFE and the impact on the chiral separations.

  Analytical chemistry 20010815

• Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.

  Synapse (New York, N.Y.) 20000201

• Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists.

  Neuropharmacology 19910601

• Antagonists of adenosine and alpha-2-adrenoceptors reverse the anticonvulsant effects of tizanidine in DBA/2 mice.

  Neuropharmacology 19890301

• Norepinephrine inhibition of pulsatile LH release: receptor specificity.

  The American journal of physiology 19860201

• Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist.

  Journal de pharmacologie 19850101

• [Comparative study of piperoxan and 2-(2-imidazolinyl)-1, 4-benzodioxane (170 150) on pre- and postsynaptic receptors in the rat].

  Journal de pharmacologie 19820101

• Pharmacological characteristics of spinal alpha-adrenoreceptors in rats.

  Journal of autonomic pharmacology 19810301

• Noradrenergic influences on sound-induced seizures.

  The Journal of pharmacology and experimental therapeutics 19800801

• The role of alpha receptors in the facilitation of the chemoreflex and inhibition of the carotid occlusion reflex by clonidine.

  Clinical and experimental hypertension 19800101

• A comparison of the cardiovascular effects of centrally administered clonidine and adrenaline in the anaesthetized rat.

  The Journal of pharmacy and pharmacology 19790101

• Differentiation of drugs acting centrally upon the cardiovascular system by means of sympathetic and vagal responses.

  Clinical and experimental hypertension 19780101

• Cardiovascular changes in anaesthetised rats after the intra-hypothalamic administration of adrenaline.

  Clinical and experimental hypertension 19780101